Table 1.
Descriptive statistics for the sample by category of oral cancer medication at baseline (n=274)
| Drug category | ||||
|---|---|---|---|---|
| Cytotoxics* (n=95), n (%) | Kinase inhibitors† (n=129), n (%) | Sex hormone inhibitors‡ (n=27), n (%) | Other§ (n=23), n (%) | |
| Sex | ||||
| Male (n=138) | 45 (47) | 58 (45) | 27 (100) | 8 (35) |
| Female (n=136) | 50 (53) | 71 (55) | 0 | 15 (65) |
| Site of cancer | ||||
| Breast | 16 (16.84) | 36 (27.91) | 0 | 5 (21.74) |
| Colorectal | 30 (31.58) | 8 (6.20) | 0 | 0 |
| GI | 20 (21.05) | 3 (2.33) | 0 | 1 (4.35) |
| Leukemia | 0 | 13 (10.08) | 0 | 2 (8.7) |
| Lymphoma | 0 | 2 (1.55) | 0 | 2 (8.7) |
| Liver | 1 (1.05) | 10 (7.75) | 0 | 0 |
| Lung | 2 (2.11) | 12 (9.30) | 0 | 0 |
| Melanoma | 1 (1.05) | 7 (5.43) | 0 | 0 |
| Myeloma | 0 | 0 | 0 | 7 (30.43) |
| Pancreatic | 22 (23.16) | 1 (0.78) | 0 | 4 (17.39) |
| Prostate | 0 | 1 (0.78) | 26 (96.30) | 0 |
| Sarcoma | 1 (1.05) | 13 (10.08) | 0 | 1 (4.35) |
| Brain | 2 (2.11) | 0 | 0 | 0 |
| Renal | 0 | 23 (17.83) | 1 (3.70) | 1 (4.35) |
| Completed week 8 | 81 (85.26) | 110 (85.27) | 26 (96.30) | 19 (82.61) |
| Age at baseline, mean (SD) | 59.8 (12.5) | 60.33 (11.00) | 70 (8.50) | 63.08 (11.00) |
*Cytotoxics included capecitabine, temozolomide, tipiracil, trifluridine, †Kinase inhibitors included crizotinib, erlotinib, gefitinib, imatinib, lapatinib, pazopanib, regorafenib, sorafenib, sunitinib, ‡Sex hormones included enzalutamide, letrozole, and abiraterone acetate, §Other category: Everolimus, olaparib, vorinostat. SD: Standard deviation, GI: Gastrointestinal